Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Journal of Immunology (Baltimore, Md. : 1950)|November 14, 2020
Glycine 236 in the Lower Hinge Region of Human IgG1 Differentiates FcγR from Complement Effector FunctionMaximilian Brinkhaus, Ruben G J Douwes, Arthur E H Bentlage, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2017
Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced MalignanciesPhilippe Aftimos, Christian Rolfo, Sylvie Rottey, et al.
Molecular Therapy. Methods & Clinical Development|April 26, 2021
VEGFR-1/Flt-1 inhibition increases angiogenesis and improves muscle function in a mouse model of Duchenne muscular dystrophyJennifer Bosco, Zhiwei Zhou, Sofie Gabriëls, et al.
Nature Medicine|July 1, 2020
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agentsCarsten Riether, Thomas Pabst, Sabine Höpner, et al.
Science (New York, N.Y.)|May 25, 2019
Protein crystallization promotes type 2 immunity and is reversible by antibody treatmentEmma K Persson, Kenneth Verstraete, Ines Heyndrickx, et al.
Nature Communications|September 12, 2020
Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancerGrégoire de Streel, Charlotte Bertrand, Nicolas Chalon, et al.
Cancer Research|July 5, 2015
Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET SignalingAnna Hultberg, Virginia Morello, Leander Huyghe, et al.
The Journal of Allergy and Clinical Immunology|September 14, 2020
ARGX-117, a therapeutic complement inhibiting antibody targeting C2Inge Van de Walle, Karen Silence, Kevin Budding, et al.
Neurology|May 24, 2019
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravisJames F Howard, Vera Bril, Ted M Burns, et al.
Nature Medicine|August 22, 2017
A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levelsSumeet A Khetarpal, Xuemei Zeng, John S Millar, et al.
Pageof 7